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When human peripheral blood mononuclear cells (PBM) are
exposed to the cytokine interleukin-2 (IL-2) in vitro, they
develop a potent cytotoxic ability referred to as lymphokine-
activated killer cell (LAK-cell) activity. LAK-cell activity is
characterised by the ability to kill fresh tumour cells in a
non-MHC-restricted manner, while leaving normal cells (e.g.
lymphocytes) unaffected (Rosenberg & Lotze, 1986). For this
reason, LAK-cells have attracted much attention as potential
tools in the treatment of advanced human malignant disease
and have been used clinically. There have been notable
successes, particularly in the case of melanoma and renal cell
carcinoma; nevertheless, the general efficacy of LAK-cell
therapy has not been as great as originally envisaged
(Rosenberg et al., 1985; Rosenberg, 1988).
Several cell-types appear to contribute to the development
of LAK-cell activity under the influence of IL-2, particularly
T-cells, natural killer (NK) cells and large granular
lymphocytes (Damle et al., 1986; Kalland et al., 1987).
However, LAK-cells differ from NK-cells in being able to
kill a range of targets known to be resistant to NK activity
(Grimm et al., 1982).
As a rule, LAK-cells cannot be isolated ex vivo. Although
the reasons for this are unclear, it is known that the
induction of human LAK-cells in vitro can be inhibited by
interleukin-4 (IL-4), which is present during the developing
immune response (Brookes & Rees, 1988; Gallagher et al.,
1988). Our previous report described the effect of IL-3 and
IL-4 on the ability of human LAK-cells to kill the ovarian
cancer cell line OWmMl. The study reported here extends
these observations in a more clinical direction by increasing
the range of cytokines tested and by using primary human
tumour cells as targets, as a step towards examining the role
of cytokines on in vivo human LAK-cell function.
LAK-cells were generated from blood donated by healthy
adult volunteers selected from the laboratory staff. PBM
were isolated from these samples by density centrifugation
over Ficol-Hypaque (Pharmacia) and stimulated with
200unitsml-1 recombinant human IL-2 (Koch-Light Ltd)
for 4 days. The culture medium employed was Ham's FIO,
supplemented with 10% (v/v) fetal calf serum and containing
a final concentration of 4mM glutamine (all media
components were obtained from Flow Laboratories
Rickmansworth, UK); cells were maintained at 37°C in a
5% CO2 humidified atmosphere.
The target cells used were either the ovarian cancer cell-
line OWmM1, which we have previously shown to be
antigenically representative of mucinous cystadenocarcinoma
(Al-Azzawi et al., 1987) or primary material obtained during
standard cytoreductive surgery; primary samples were
confirmed as being malignant and cells were taken from
non-necrotic tissue. Ovan-I and Ovan-2 were derived from
ovarian cancer patients at Stobhill Hospital, Glasgow while
Ovan-3 and Bwl-1 were from ovarian and bowel cancer
patients, respectively, from Addenbrookes Hospital,
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Cambridge. The killing assay was conducted over a period of
18h. This prolonged assay was deliberately chosen over the
more usual 4h chromium-release assay in an attempt to
mimic in vivo conditions more closely, where LAK-cells are
expected to remain active for prolonged periods. In addition,
the adherent nature of the target cells allowed us to measure
the remaining live cells directly with the aid of the reducable
dye MTT [3-(4,5-dimethylthoazol-2-yl)-2,5-diphenyl tetra-
zolium bromide]. The percentage viability of the target cells
was established following their exposure to the LAK-cells
(Mosmann, 1983; Gallagher et al., 1988).
Thus, target cells were exposed to LAK-cells at an
effector-to-target (E:T) cell ratio of 5:1 for 18h in 96-well,
flat-bottom plates (Sterilin). It was usual for 5 x 104 target
cells to be placed in each well. At the end of the assay
period, LAK-cells and dead target cells were removed by
gentle but thorough washing and the culture fluid replaced
with complete medium containing 0.5mgml-l MTT. Four
hours later, all the medium was carefully removed from each
well and replaced with 200yI of dimethylsulphoxide.
Following gentle agitation, the colour density was
established as A 59 A calibration curve (cell number
x A595) was established for each target cell type and used to
determine the number of viable cells remaining in each
experimental well. The percentage killing achieved was then
calculated by direct comparison of the test wells with control
wells, which contained target cells but no LAK-cells. Six
replicate wells were established per test point.
Recombinant human cytokines were obtained from Koch-
Light Ltd (Haverhill, UK). A range of concentrations of
each material was employed, in order to straddle that
required for optimal activity in the biological system
normally used to characterise particular cytokines (for
example, the thymocyte co-stimulator assay for IL-1), as
described by the manufacturers. The concentrations reported
here represent the highest tested in our experiments: IL-1,
200unitsml-1; IL-2, 200unitsml-1; IL-3, 1,000unitsml-1;
IL-4, 1,000unitsml-1; IL-6, 1,000unitsml- and GM-CSF,
1,000unitsml-1. These concentrations were found to be the
most effective here and in our previous study (Gallagher et
al., 1988). It should be pointed out that the units described
here are meaningless in terms of their biological activity on
LAK-cells, since such effects are poorly defined. The
nomenclature is retained to provide a reference to the
amount of material present.
We first examined the ability of the cytokines themselves
to affect the growth of the tumour cells, in the absence of
LAK-cells. The experimental results are shown in Table I.
The target cells were exposed to the cytokines for the full
18h of the assay period, then their viability was assessed by
the MTT method. The results clearly show that the cytokines
were not able to cause the death of the established cell-line,
or the primary ovarian or bowel tumour material.
As a prelude to investigating the ability of cytokines to
regulate LAK-cell function, we first demonstrated that the
cytokines did not increase the resistance or susceptibility of
the target cells to LAK-cell lysis (data not shown). This was
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Table I Cytokines' influence on human LAK-cell function
Percentage killing
OWmMI OVAN-I OVAN-2 OVAN-3 BWL-J
Medium alone 0 0 0 0 0
IL-1 3 n.d. 7 0 2
IL-2 0 8 4 5 -9
IL-3 0 3 n.d. n.d. 2
IL-4 0 -2 0 -3 n.d.
IL-6 0 n.d. -4 0 n.d.
GM-CSF 6 4 0 n.d. 8
LAK-cells alone 74+8 83+ 12 28+7 41+ 14 68+20
LAK-cells+ILL-1 79+12 n.d. 32+6 41+2 77+3
LAK-cells+IL-6 79+ 13 n.d. 34+7 35+ 13 n.d.
LAK-cells+GM-CSF 75+10 88+4 21+4 n.d. 68+8
LAK-cells+IL-3 21*+2 52*+3 n.d. n.d. 11*+l
LAK-cells+IL-4 42* + 1I 30*+11 2*+I 37*+ 12 n.d.
LAK-cells+IL-2 >99* >99* 52*+11 78*+4 81*+14
Cytokines were tested for their ability to kill tumour cells and to influence the
ability of LAK-cells to kill these tumour cells. Cytokines were added for the full 18h
of the assay period at the following concentrations: IL-1 and IL-2, 200Uml-1; IL-3,
IL-4, IL-6 and GM-CSF, 1,00OUml-P. The percentage killing was calculated as
described in the text; the mean + standard deviation of killing achieved in six
replicate wells is shown.
n.d.=not determined. Figures marked with an asterisk are significantly different
from the appropriate 'LAK-cells alone' group (Student's t test; see text).
achieved by pre-incubating the target cells with the
appropriate cytokine for 6h then washing carefully before
the 18h killing period. The ability of these cytokines to
affect the killing of the target cells by the LAK-cells was
then investigated. A different LAK-cell donor was used for
each target cell type, for reasons of availability, and the
cytokines were again present for the whole of the assay
period. The experimental results are shown in Table I. The
cytokines fell into three clear groups. The first group (IL-1,
IL-6 and GM-CSF) did not affect the ability of LAK-cells to
kill tumour targets. The second group (IL-3 and IL-4)
greatly reduced the observed killing. This inhibition was
effectively complete in the case of IL-4 and the Ovan-2
target, but substantial reductions in killing were observed
whenever IL-3 or IL-4 was present with the LAK-cells.
Finally, the presence of IL-2 greatly enhanced the ability of
LAK-cells to kill human tumour-cell targets. For all target
cell types examined, the results obtained from the LAK-
cells+IL-2, LAK-cells+IL-3 and IL-4 experiments were
significantly different (greater killing with IL-2, less with IL-
3 and IL-4; Student's t test, P<0.05) from the appropriate
'LAK-cells alone' experiment.
Thus, it is clear from the results described here that
certain cytokines are able to regulate the effector function of
human LAK-cells. While the enhancing effect of IL-2 on
tumour cell killing was to be expected, the ability of IL-3
and IL-4 to inhibit the ability of human LAK-cells to kill
primary human tumours ex vivo suggests that cytokines
encountered within the body may reduce the efficiency of
LAK-cell therapy. Because of the intimate nature of the
contact between cells which produce and respond to
cytokines in vivo, the concept of concentration has no
meaning in an in situ context. So, although our results
indicate that LAK-cells are subject to cytokine-mediated
control, it is not possible to extrapolate these in vitro data to
serum concentrations, for example. Both IL-3 and IL-4 have
been observed as being able to reduce the efficiency of
human LAK-cell induction (Brookes & Rees, 1988;
Gallagher et al., 1988) (although IL-4 is reported to enhance
the induction of murine LAK-cells (Mule et al., 1987; Pearce
et al., 1988). It will be interesting to examine IL-1, IL-6 and
GM-CSF in this respect even though they were inactive on
the effector phase of LAK-cell function, as described here.
The pure nature of the cytokines used here does not
guarantee that the inhibitions observed with IL-3 and IL-4
are direct effects. The heterogeneous nature of the starting
PBM population and of those cell types known to contribute
to the generation of LAK-cell activity does not preclude the
possibility that these cytokines are (for example) initiating
interactions between T-cells and NK-cells in the LAK-cell
population, which result in a reduction in observed target-
cell killing. Any such ability to induce cell interactions is just
as relevant as potential direct inhibitory effects, when the
clinical implications are considered. Although the mechanism
of action of IL-3 and IL-4 is not defined in this system, IL-3
is known to inhibit strongly the development of mouse NK-
cells in vivo and this may be contributing to the phenomenon
described here (Kalland, 1986, 1987).
The therapeutic protocols involving LAK-cells call for
these cells to be introduced to the patient in the presence of
large amounts of IL-2 (Rosenberg et al., 1985). However,
cytokines interact with one another to regulate the immune
response and these interactions can either enhance (Schuller
et al., 1987) or suppress (Hoffman, 1986) immunological
function. Thus, it appears that the immunological
environment within individual patients or their tumours can
adversely affect the efficacy of adoptively transferred killer
cells. These relationships are of particular interest when
attempting to design anti-tumour protocols based around
manipulations of the patient's own immune system (Guillou,
1987) and may have serious implications for the design of
combined immunotherapeutic protocols which involve
treatment with cytokines other than IL-2, in combination
with LAK-cells.
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